Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In the OlympiA study, 1 year of adjuvant olaparib significantly extended invasive disease-free survival and overall survival. The benefit was consistent across subgroups, and this regimen is now recommended after chemotherapy for germline BRCA1/2 mutation (gBRCA1/2m) carriers with high-risk, HER2-negative early breast cancer. However, the integration of olaparib in the landscape of agents currently available in the post(neo)adjuvant setting-ie, pembrolizumab, abemaciclib, and capecitabine-is challenging, as there are no data suggesting how to select, sequence, and/or combine these therapeutic approaches. Furthermore, it is unclear how to best identify additional patients who could benefit from adjuvant olaparib beyond the original OlympiA criteria. Since it is unlikely that new clinical trials will answer these questions, recommendations for clinical practice can be made through indirect evidence. In this article, we review available data that could help guide treatment decisions for gBRCA1/2m carriers with high-risk, early-stage breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322138 | PMC |
| http://dx.doi.org/10.1093/oncolo/oyad123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial.
Trials
September 2025
Independent Laboratory of Translational Medicine, Chair of Medical Genetics, Medical University of Lublin, Lublin, Poland.
The management of advanced ovarian cancer has significantly developed with the integration of bevacizumab into standard therapeutic regimens. While the efficacy of bevacizumab has been established in trials such as GOG218, ICON7, and PAOLA-1, there remains a gap in understanding the advantages of the 7.5 mg/kg dose over the 15 mg/kg regimen.
View Article and Find Full Text PDFShort- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer.
Am J Cancer Res
July 2025
Department of Breast Surgery, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University Taiyuan 030000, Shanxi, China.
Objective: To evaluate the short- and long-term efficacy of olaparib combined with chemotherapy as adjuvant therapy in patients with advanced triple-negative breast cancer (TNBC).
Methods: This retrospective cohort study included 274 patients with advanced TNBC, divided into an observation group (olaparib + chemotherapy, n = 116) and a control group (chemotherapy alone, n = 158). Primary outcome measures included Objective Response Rate (ORR), Disease Control Rate (DCR), immune function indicators (CD3+, CD4+/CD8+ ratio, Natural Killer T cells), cytokine levels (Interferon-gamma, Interleukin-2, Interleukin-6), tumor markers [Carcinoembryonic Antigen, Carbohydrate Antigen 153, Human Epididymis Protein 4], Karnofsky Performance Status (KPS), Progression-Free Survival (PFS), Overall Survival (OS), and adverse event incidence.
Q and a on PARP inhibitor use in somatic BRCA-mutated breast cancers.
J Natl Cancer Inst
August 2025
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Science, Little Rock, AR, USA.
Individuals with pathogenic variants in BRCA1 or BRCA2 genes (BRCAm) have an increased risk of developing breast, ovarian, pancreatic, and prostate cancers. BRCAm can be of germline origin (inherited; gBRCAm) or arise spontaneously during tumor development (somatic BRCAm; sBRCAm). gBRCAm status is determined by analyzing DNA from non-tumor cells in blood or saliva.
View Article and Find Full Text PDFWe present a case of a 71-year-old woman with a history of high-grade serous ovarian adenocarcinoma, treated with neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy. A maintenance treatment combining bevacizumab and olaparib was introduced consecutively. Bevacizumab was stopped 7 months later due to neurological complications.
View Article and Find Full Text PDFOptimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers.
Curr Oncol
July 2025
Faculty of Medicine and School of Pharmacy, Memorial University of Newfoundland, St John's, NL A1B 3V6, Canada.
The adjuvant treatment landscape for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) is rapidly evolving, with a diverse range of therapeutic options-including endocrine therapies, bisphosphonates, ovarian function suppression, olaparib, CDK4/6 inhibitors, and emerging agents such as immunotherapy. While these advances have markedly improved patient outcomes, they also introduce challenges related to implementation, monitoring, and resource allocation. Notably, therapies like CDK4/6 inhibitors require particularly close monitoring, creating logistical and capacity challenges for medical oncologists, whose workloads are already stretched due to rising cancer incidence and treatment complexities.
View Article and Find Full Text PDF